(No ratings)
Dr. Deepakbabu Chellapandian, MD is an oncologist in Saint Petersburg, FL specializing in oncology (cancer care). Dr. Deepakbabu Chellapandian, MD is affiliated with Johns Hopkins All Children's Outpatient Care, St. Petersburg.
He has a state license in Florida.
Licensed In: Florida
Dr. Deepakbabu Chellapandian, MD does not have any reviews yet, be the first to leave a review of Dr. Deepakbabu Chellapandian, MD here: Leave a Review
(No ratings)
These charts describe general payments received by Dr. Deepakbabu Chellapandian, MD. Doctors may receive payments for a number of reasons, including meal compensation, travel compensation, and consulting.
| Sobi, Inc |
$203
GAMIFANT $203 |
|---|---|
| bluebird bio, Inc. |
$106
LYFGENIA $106 |
| Astellas Pharma US Inc |
$29
Cresemba $29 |
| ADMA BioManufacturing LLC |
$27
$27 |
| Food and Beverage | $243 |
|---|---|
| Education | $95 |
| Consulting Fee | $27 |
Dr. Deepakbabu Chellapandian, MD has received 58 research payments totaling $301,067.
Dr. Chellapandian is the division chief of blood and marrow transplant and specializes in bone marrow transplant as a hematologist-oncologist and serves as Director of the Center for Cell and Gene Therapy for Non-Malignant Conditions (CCGNC) in the Johns Hopkins All Children’s Cancer & Blood Disorders Institute. He joined the hospital staff in 2017. Dr. Chellapandian earned his medical degree from Madurai Medical College and then trained at Postgraduate Institute of Medical Education and Research, both in India. He completed a residency in pediatrics at Albert Einstein Medical Center in Philadelphia. Dr. Chellapandian completed a pediatric hematology-oncology and bone marrow transplantation fellowship at Hospital for Sick Children/University of Toronto and an advanced fellowship on bone marrow transplantation and cellular therapy at St. Jude Children’s Research Hospital in Memphis, Tennessee.Dr. Chellapandian's clinical and research interests include hematopoietic stem cell transplant for primary immunodeficiency, immune dysregulation disorders, sickle cell disease, thalassemia, and treatment of histiocytic disorders. He has special focus on ex-vivo graft engineering techniques and autologous gene therapy. He has adapted new methods of T- cell depletion using haploidentical transplantation to transplant patients lacking a suitable matched donor. He has numerous scientific papers and review articles published in this field.